AbbVie Inc. Q3 FY2026 Earnings Call Summary

ABBV NYSE Healthcare 📅 2026-07-31 ⏱ ~60 sec read 🟢 Bullish

⏱️ 60-Second Brief AbbVie Inc. · Q3 FY2026

Revenue

$16.990B

EPS

$224

AI Sentiment

🟢 Bullish

The company demonstrated robust growth in key therapeutic ar…

📌 Bottom Line: AbbVie delivered a strong second quarter in 2026, reporting net revenues of $16.990 billion, a significant 10.2% increase year-over-year, propelled by robust performance in its immunology and neuroscience portfolios. The…

🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy. · ⚠️ Not financial advice. For informational purposes only. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-07-31 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

AbbVie delivered a strong second quarter in 2026, reporting net revenues of $16.990 billion, a significant 10.2% increase year-over-year, propelled by robust performance in its immunology and neuroscience portfolios. The company also announced a strategic $10.9 billion acquisition of Apogee Therapeutics to further bolster its immunology pipeline, leading to a slight adjustment in its full-year adjusted EPS guidance.

📊 Key Financial Metrics

Revenue $16.990B

EPS (Diluted) $224

YoY Revenue Growth 10.2%

Gross Margin 84.7%

AI Sentiment 🟢 Bullish The company demonstrated robust growth in key therapeutic areas, successfully navigating patent expirations, and made a significant strategic acquisition to secure future growth, reinforcing its long-term outlook and innovation capabilities.

✅ What Went Well

✅ AbbVie achieved worldwide net revenues of $16.990 billion, representing a strong 10.2% increase on a reported basis year-over-year, underscoring the company's successful commercial execution and strong demand for its diverse product offerings.

✅ The immunology segment continued to be a powerhouse, with global net revenues reaching $8.786 billion, marking an impressive 15.1% increase, largely driven by the outstanding performance of Skyrizi, which surged 24.4% to $5.505 billion, and Rinvoq, which grew 24.5% to $2.525 billion.

✅ The neuroscience portfolio delivered significant growth, with global net revenues increasing by 20.3% to $3.228 billion, propelled by key products such as Vraylar, which saw an 18.9% increase to $1.071 billion, and Botox Therapeutic, growing 12.2% to $1.042 billion.

✅ The announced definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion is a major strategic win, expected to significantly bolster AbbVie's immunology pipeline with promising clinical-stage candidates, positioning the company for sustained long-term growth and leadership.

✅ AbbVie secured several important regulatory approvals, including expanded indications for Skyrizi and Rinvoq in various inflammatory conditions, approval for Aquipta in acute migraine, and Decnupaz for blastic plasmacytoid dendritic cell neoplasm (BPDCN), demonstrating robust R&D and market expansion efforts.

⚠️ Concerns & Risks

⚠️ Global net revenues for Humira continued their significant decline, decreasing by 35.9% to $756 million, reflecting the ongoing and intensifying impact of biosimilar competition in key markets, alongside a substantial 29.4% decrease in Imbruvica revenues to $532 million.

⚠️ The oncology portfolio as a whole experienced a slight decrease in global net revenues of 1.5% to $1.650 billion, with the significant decline in Imbruvica revenues overshadowing growth from Venclexta and Elahere, indicating mixed performance and potential headwinds.

⚠️ The aesthetics portfolio showed minimal growth, with global net revenues increasing only 0.3% on a reported basis and actually decreasing 0.9% on an operational basis, suggesting a challenging market environment or increased competitive pressures, particularly for Juvederm, which experienced a 6.0% decrease.

⚠️ AbbVie updated its full-year 2026 adjusted diluted EPS guidance range downwards, from $13.91 - $14.11 to $13.87 - $14.07, attributed to the $0.14 per share dilutive impact from the proposed Apogee acquisition and an unfavorable $0.58 per share related to acquired IPR&D and milestones expense.

⚠️ While strategically important, the $10.9 billion acquisition of Apogee Therapeutics introduces inherent integration risks, including the potential for higher-than-expected integration costs, challenges in fully realizing anticipated benefits, and the diversion of management's attention from ongoing business operations.

🔮 CEO / Management Guidance

AbbVie updated its adjusted diluted EPS guidance for the full year 2026, narrowing the range from its previous $13.91 - $14.11 to a revised $13.87 - $14.07. This updated outlook specifically accounts for a $0.14 per share dilutive impact stemming from the proposed acquisition of Apogee Therapeutics, which is expected to finalize in the third quarter of 2026. Additionally, the guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter. Despite these adjustments, Chairman and CEO Robert A. Michael expressed strong confidence in AbbVie's "very strong" long-term outlook.

💬 Key Quote

AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement. We also announced the proposed acquisition of Apogee Therapeutics, which strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value." — Robert A. Michael, Chairman and Chief Executive Officer

📅 Quarter-over-Quarter Comparison

Comparing Q3 FY2026 vs Q2 FY2026 All quarters →

Sentiment 🟡 Neutral → 🟢 Bullish

🏢 About AbbVie Inc.

AbbVie Inc. (ABBV) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

ABBV NYSE Healthcare All AbbVie Inc. Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

Topics: Immunology Drug Performance Neuroscience Portfolio Expansion Strategic Mergers & Acquisitions Pharmaceutical Pipeline Development Biosimilar Competition Management

📁 More from AbbVie Inc.

View all earnings summaries for AbbVie Inc. →